Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy

Background— End stage (ES) is a recognized part of the hypertrophic cardiomyopathy (HCM) disease spectrum. Frequency, clinical profile and course, and treatment strategies in these patients remain incompletely defined. Methods and Results— Three HCM cohorts comprised 1259 patients, including 44 (3.5%) characterized as ES with systolic dysfunction (ejection fraction <50% at rest; range 15% to 49%). ES developed at a wide age range (14 to 74 years), with 45% of patients ≤40 years old. Although 29 patients (66%) died of progressive heart failure, had sudden death events, or underwent heart transplantation, 15 (34%) survived with medical management over 3±3 years. Duration from onset of HCM symptoms to ES identification was considerable (14±10 years), but ES onset to death/transplantation was brief (2.7±2 years). ES occurred with similar frequency in patients with or without prior myectomy (P=0.84). Appropriate defibrillator interventions were 10% per year in patients awaiting donor hearts. Most ES patients (n=23; 52%) showed substantial left ventricular (LV) remodeling with cavity dilatation. Less complete remodeling occurred in 21 patients (48%), including 5 with persistence of a nondilated and markedly hypertrophied LV. Pathology and magnetic resonance imaging showed extensive (transmural) fibrosis in 9 of 11 ES patients. At initial evaluation, patients who developed ES were younger with more severe symptoms, had a larger LV cavity, and more frequently had a family history of ES than other HCM patients. Conclusions— ES of nonobstructive HCM has an expanded and more diverse clinical expression than previously appreciated, including occurrence in young patients, heterogeneous patterns of remodeling, frequent association with atrial fibrillation, and impaired LV contractility that precedes cavity dilatation, wall thinning, and heart failure symptoms. ES is an unfavorable complication (mortality rate 11% per year) and a sudden death risk factor; it requires vigilance to permit timely recognition and the necessity for defibrillator implantation and heart transplantation.

[1]  G. Boriani,et al.  Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. , 2005, Journal of the American College of Cardiology.

[2]  W. Mckenna,et al.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.

[3]  Dudley J Pennell,et al.  The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[4]  Barry J Maron,et al.  American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, Journal of the American College of Cardiology.

[5]  I. Olivotto,et al.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[6]  R. Levine,et al.  Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. , 2003, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  M. Link,et al.  Primary prevention of sudden death as a novel treatment strategy in hypertrophic cardiomyopathy. , 2003, Circulation.

[8]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[9]  K. Chien,et al.  Genotype, phenotype: upstairs, downstairs in the family of cardiomyopathies. , 2003, The Journal of clinical investigation.

[10]  B. Maron.  Hypertrophic cardiomyopathy: a systematic review. , 2002, JAMA.

[11]  J. Seidman,et al.  The Genetic Basis for Cardiomyopathy from Mutation Identification to Mechanistic Paradigms , 2001, Cell.

[12]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[13]  G Thiene,et al.  Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. , 2000, Human pathology.

[14]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[15]  B. Maron,et al.  Implications of left ventricular remodeling in hypertrophic cardiomyopathy. , 1998, The American journal of cardiology.

[16]  T. Ino,et al.  Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. , 1997, The American journal of cardiology.

[17]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[18]  O. Hess,et al.  Left ventricular chamber dilatation in hypertrophic cardiomyopathy: related variables and prognosis in patients with medical and surgical therapy. , 1995, British heart journal.

[19]  Y. Sugishita,et al.  Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[20]  O. Hess,et al.  Risk factors for systolic dysfunction and ventricular dilatation in hypertrophic cardiomyopathy. , 1994, International journal of cardiology.

[21]  W. Roberts,et al.  Clinicopathologic features of hypertrophic cardiomyopathy managed by cardiac transplantation. , 1993, The American journal of cardiology.

[22]  W. Roberts,et al.  Coexistence of sudden cardiac death and end-stage heart failure in familial hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[23]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[24]  S. Larson,et al.  Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. , 1987, Circulation.

[25]  R. Bonow,et al.  Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy. , 1987, The American journal of cardiology.

[26]  Z. Krajcer,et al.  Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: higher incidence in patients with midventricular obstruction. , 1987, Journal of the American College of Cardiology.

[27]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[28]  Z. Krajcer,et al.  Coronary artery disease in hypertrophic cardiomyopathy. , 1985, The American journal of cardiology.

[29]  H. Ishibashi-Ueda,et al.  Three autopsy cases of progression to left ventricular dilatation in patients with hypertrophic cardiomyopathy. , 1985, American heart journal.

[30]  S. Sasayama,et al.  Progression from hypertrophic obstructive cardiomyopathy to typical dilated cardiomyopathy-like features in the end stage. , 1984, Japanese circulation journal.

[31]  M. Fujino,et al.  Seventeen year follow-up of a patient with hypertrophic cardiomyopathy which progressed to dilated cardiomyopathy. , 1984, Japanese heart journal.

[32]  H. Gutgesell,et al.  Progression from hypertrophic obstructive cardiomyopathy to congestive cardiomyopathy in a child. , 1982, American heart journal.

[33]  J. Roelandt,et al.  Progression to left ventricular dilatation in patients with hypertrophic obstructive cardiomyopathy. , 1979, American heart journal.

[34]  W. Roberts,et al.  Hypertrophic cardiomyopathy and transmural myocardial infarction without significant atherosclerosis of the extramural coronary arteries. , 1979, The American journal of cardiology.

[35]  W. Roberts,et al.  Quantitative Analysis of Cardiac Muscle Cell Disorganization in the Ventricular Septum of Patients with Hypertrophic Cardiomyopathy , 1979, Circulation.

[36]  E. D. Wigle,et al.  Expert consensus document American College of Cardiology / European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy , 2003 .

[37]  W. Roberts,et al.  Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death. , 2000, Journal of the American College of Cardiology.